[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1099
61. Gahine R, Sudarshan V, Hussain N, Krishnani C: Pleomorphic adenoma: A diagnostic pitfall in the diagnosis of salivary gland lesions on FNAC: Case reports with review of the literature. Cytojournal; 2010;7:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma: A diagnostic pitfall in the diagnosis of salivary gland lesions on FNAC: Case reports with review of the literature.
  • Fine needle aspiration cytology (FNAC) is commonly being used with increasing frequency for the pre-operative evaluation of salivary gland lesions.
  • The most frequent problems involve variations in the expected cytology of pleomorphic adenoma (PA).
  • Salivary gland FNACs performed at Pt.
  • As PA is the most common salivary gland neoplasm, it should always be considered and ruled out as the first differential in the diagnosis of salivary gland FNACs.
  • To document the same, we advocate liberal use of repeat aspirations with multiple sampling performed from different parts of the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976206.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2955342
  • [Keywords] NOTNLM ; FNA salivary gland / pitfalls of diagnosis / pleomorphic adenoma / variability of tumor morphology
  •  go-up   go-down


62. Beil CM, Keberle M: Oral and oropharyngeal tumors. Eur J Radiol; 2008 Jun;66(3):448-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral and oropharyngeal tumors.
  • There is a large variability of tumors and tumor-like lesions, which are located in the oral cavity and oropharynx.
  • But more than 90% of all tumors in this area are squamous cell carcinomas (SCCs).
  • About 10% of all oral and oropharyngeal tumors are benign.
  • Acquired lesions can be inflammatory (abscess) or neoplastic (pleomorphic adenoma and hemangioma).

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457933.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 18
  •  go-up   go-down


63. Affolter A, Helmbrecht S, Finger S, Hörmann K, Götte K: Altered expression of cell cycle regulators p21, p27, and p53 in tumors of salivary glands and paranasal sinuses. Oncol Rep; 2005 Jun;13(6):1089-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of cell cycle regulators p21, p27, and p53 in tumors of salivary glands and paranasal sinuses.
  • In several human tumors, a loss of these proteins is associated with poor clinical outcome.
  • The role of these cell cycle regulators in tumors of salivary gland and paranasal sinus origin is still unclear.
  • In this study it was intended to demonstrate and compare the expression of p21, p27, and p53 in benign and malignant tumors of salivary glands and paranasal sinuses.
  • Nine adenoid cystic carcinomas, 5 adenocarcinomas, 4 cylindrical cell carcinomas, as well as 30 pleomorphic adenomas and 26 inverted papillomas, were studied.
  • All malignant tumors turned out to be positive for p21 after performing TSA-IHC, although 72% of those samples had shown weak to negative protein levels in conventional immunostaining.
  • The study sheds new light upon the role of CIP/KIP protein family in tumors of salivary glands and paranasal sinuses.
  • Furthermore, it is the first description of p21 and p53 TSA-IHC in these tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenoid Cystic / metabolism. Cell Cycle Proteins / metabolism. Paranasal Sinus Neoplasms / metabolism. Paranasal Sinuses / metabolism. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870926.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


6
Advertisement
4. Miguita L, Martinez EF, de Araújo NS, de Araújo VC: FGF-2, TGFbeta-1, PDGF-A and respective receptors expression in pleomorphic adenoma myoepithelial cells: an in vivo and in vitro study. J Appl Oral Sci; 2010 Jan-Feb;18(1):83-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FGF-2, TGFbeta-1, PDGF-A and respective receptors expression in pleomorphic adenoma myoepithelial cells: an in vivo and in vitro study.
  • Myoepithelial cells have an important role in salivary gland tumor development, contributing to a low grade of aggressiveness of these tumors.
  • The importance of stromal cells and growth factors during tumor initiation and progression has been highlighted by recent literature.
  • Many tumors result from the alteration of paracrine growth factors pathways.
  • OBJECTIVES: This study evaluated the expression of fibroblast growth factor-2 (FGF-2), transforming growth factor beta-1 (TGFbeta-1), platelet-derived growth factor-A (PDGF-A) and their respective receptors (FGFR-1, FGFR-2, TGFbetaR-II and PDGFR-alpha) in myoepithelial cells from pleomorphic adenomas (PA) by in vivo and in vitro experiments.
  • Myoepithelial cells were obtained from explants of PA tumors provided by surgery from different donors.
  • CONCLUSIONS: These data suggested that FGF-2 compared to the other studied growth factors has an important role in PA benign myoepithelial cells, probably contributing to proliferation of these cells through the FGFR-1.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Fibroblast Growth Factor 2 / analysis. Platelet-Derived Growth Factor / analysis. Protein-Serine-Threonine Kinases / analysis. Receptor, Fibroblast Growth Factor, Type 1 / analysis. Receptor, Fibroblast Growth Factor, Type 2 / analysis. Receptor, Platelet-Derived Growth Factor alpha / analysis. Receptors, Transforming Growth Factor beta / analysis. Salivary Gland Neoplasms / pathology. Transforming Growth Factor beta1 / analysis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):249-60 [16807804.001]
  • [Cites] J Oral Pathol Med. 2001 Aug;30(7):413-20 [11488419.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):98-104 [10211317.001]
  • [Cites] Exp Cell Res. 1993 Feb;204(2):247-59 [8440322.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):113-22 [12710942.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):390-7 [18992915.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):1011-6 [16757205.001]
  • [Cites] EMBO J. 1990 May;9(5):1511-7 [2328724.001]
  • [Cites] DNA Cell Biol. 2007 Dec;26(12):811-26 [18021009.001]
  • [Cites] FEBS Lett. 2000 Feb 18;468(1):6-10 [10683430.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7211-22 [9054417.001]
  • [Cites] Mech Ageing Dev. 2007 Jan;128(1):17-24 [17118424.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3750-6 [10949929.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3485-91 [12244137.001]
  • [Cites] Biomed Pharmacother. 1995;49(9):389-99 [8746075.001]
  • [Cites] Differentiation. 2006 Sep;74(7):349-64 [16916374.001]
  • [Cites] J Cell Sci. 1993 Sep;106 ( Pt 1):135-43 [8270619.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):52-60 [17143286.001]
  • [Cites] BMC Genomics. 2007 Apr 11;8:98 [17425807.001]
  • [Cites] Bioessays. 1998 May;20(5):400-11 [9670813.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e19 [18232728.001]
  • [Cites] PLoS Biol. 2008 May 6;6(5):e108 [18462018.001]
  • [Cites] Trends Genet. 2004 Nov;20(11):563-9 [15475116.001]
  • [Cites] Mol Cancer Res. 2004 Nov;2(11):643-52 [15561780.001]
  • [Cites] J Oral Pathol Med. 1997 Jan;26(1):17-22 [9021547.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2341-6 [18845558.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14 ):8430-5 [12808151.001]
  • [Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Miner Electrolyte Metab. 1998;24(2-3):111-9 [9525693.001]
  • [Cites] Differentiation. 2007 Nov;75(9):831-42 [17697126.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1307-12 [11257130.001]
  • [Cites] Oncologist. 2001;6 Suppl 5:4-7 [11700386.001]
  • [Cites] Mayo Clin Proc. 2006 Sep;81(9):1241-57 [16970222.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):121-34 [10912794.001]
  • [Cites] J Oral Pathol Med. 1998 Aug;27(7):287-92 [9725564.001]
  • [Cites] J Oral Pathol Med. 2001 Mar;30(3):159-67 [11271631.001]
  • [Cites] Traffic. 2005 Oct;6(10):947-54 [16138907.001]
  • [Cites] FEBS J. 2008 Apr;275(7):1579-92 [18312416.001]
  • [Cites] Urology. 2000 Jun;55(6):800-6 [10840080.001]
  • [Cites] Genome Biol. 2001;2(3):REVIEWS3005 [11276432.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 2;277(3):643-9 [11062007.001]
  • [Cites] J Cell Mol Med. 2007 Nov-Dec;11(6):1239-50 [18205698.001]
  • [Cites] J Pathol. 1996 Apr;178(4):429-36 [8691322.001]
  • (PMID = 20379686.001).
  • [ISSN] 1678-7765
  • [Journal-full-title] Journal of applied oral science : revista FOB
  • [ISO-abbreviation] J Appl Oral Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Actins; 0 / Calcium-Binding Proteins; 0 / Keratin-7; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Platelet-Derived Growth Factor; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Vimentin; 0 / calponin; 0 / platelet-derived growth factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


65. Vyrupaev SV: [Treatment of giant tumors of the parotid gland]. Vopr Onkol; 2005;51(1):128-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of giant tumors of the parotid gland].
  • Since large (<<giant>>) benign mixed tumors of the parotid gland are rare, there is insufficient evidence on the modalities of the facial nerve management.
  • Eight patients, aged 29-65, with tumors of more than 15 cm in diameter were operated on.
  • Tumors were located externally of the gland (5), parapharyngeally (2), or both (1).
  • The regularities between the facial nerve location and site of tumor were investigated, and it is suggested that, in difficult cases, search should start from the temporal area since it offers most access.
  • When tumor of parapharyngeal localization is excised, it is desirable to perform double osteotomy in the mental part of the mandible as well as at the point of entry of the lower of the alveolar nerve, to avoid the latter's being traumatized.
  • [MeSH-major] Parotid Gland / pathology. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909823.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement